119P - The efficacy and toxicity of chemotherapy with bevacizumab for previously treated patients with advanced non-squamous non-small cell lung cancer

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter RYO Itotani
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors R. Itotani, T. Kitajima, D. Inoue, K. Takamatsu, M. Ishitoko, S. Marumo, M. Sakuramoto, M. Fukui
  • Respiratory Disease Center, The Tazuke Kofukai Medical Research Institute KITANO HOSPITAL, 5308480 - Osaka city/JP

Abstract

Bevacizumab (Bev) including chemotherapy is recommended as first line chemotherapy for patients with advanced non-squamous non-small cell lung cancer (non-Sq NSCLC). However there are few reports on the efficacy and toxicity of chemotherapy including Bev for previously treated patients with advanced non-Sq NSCLC. We conducted a retrospective cohort study to evaluate the efficacy and toxicity of chemotherapy including Bev for previously treated patients with advanced non-Sq NSCLC.